COPD — all decisions

The Board granted service connection for chronic obstructive pulmonary disorder (COPD) based on the Veteran's conceded herbicide exposure during active service.

The Board remands the veteran's claims for further development and to correct pre-decisional errors in fulfilling its duty to assist.

The Board granted service connection for chronic obstructive pulmonary disease (COPD) as it is related to and/or aggravated by the Veteran's service-connected asbestosis.

The Board remands the claim for service connection for cause of death to correct a pre-decisional duty to assist error related to the Veteran's exposure to contaminated water at Camp Lejeune.

The Board granted service connection for COPD, right lower extremity peripheral neuropathy, and left lower extremity peripheral neuropathy based on the Veteran's exposure to Agent Orange during his service.

The Veteran was granted an initial rating of 30 percent for asthma and COPD prior to December 17, 2019, but the claims for higher ratings were denied.

The Board remands the claims for service connection for asthma, COPD, and OSA due to a pre-decisional duty to assist error.

The Board remands the claims for service connection and increased ratings to obtain additional evidence, including outstanding VA treatment records.

The Board granted an initial disability rating of 30 percent for service-connected sarcoidosis with chronic obstructive pulmonary disease, but denied a motion to revise the March 2021 rating decision based on clear and unmistakable error.

The Veteran is granted an earlier effective date of August 10, 2022, for the award of service connection for hypertension. The claim for a compensable rating and entitlement to service connection for chronic obstructive pulmonary disease (COPD) are denied.

The Board granted an earlier effective date for COPD, SMC at the statutory housebound rate, and DEA benefits. The claims for a higher rating for major depressive disorder, separate TBI rating, and earlier TDIU were remanded.

The Board denied service connection for chronic respiratory condition to include COPD, finding that the evidence rebutted the presumption of service connection under the PACT Act.

The Board granted an initial disability rating of 30 percent for service-connected sarcoidosis with chronic obstructive pulmonary disease, but denied a motion to revise the March 2021 rating decision based on clear and unmistakable error.

The Board granted an initial disability rating of 30 percent for service-connected sarcoidosis with chronic obstructive pulmonary disease, but denied a motion to revise the March 2021 rating decision based on clear and unmistakable error.

The Board denied the claim for service connection for the cause of the Veteran's death, finding that there was no evidence linking his medical conditions to his active service.

The Board denied the Veteran's claim for service connection for a respiratory disability, diagnosed as COPD, finding that the evidence does not support a causal relationship between the condition and his active military service.

The Board granted an initial disability rating of 30 percent for service-connected sarcoidosis with chronic obstructive pulmonary disease, but denied a motion to revise the March 2021 rating decision based on clear and unmistakable error.

The Board remands the claim for service connection of chronic obstructive pulmonary disease (COPD) to obtain an adequate medical opinion addressing its etiology, including considering potential toxic exposures and secondary service connection theories.

The Board remands the case to adjudicate a higher initial rating for the Veteran's service-connected respiratory disability, as the AOJ adjudicated an unclaimed issue involving clear and unmistakable error (CUE) in the ratings assigned.

The Board denied the veteran's claims for increased ratings for headaches, tinnitus, bilateral hearing loss, and sleep apnea with COPD. The veteran was granted a total disability rating based on individual unemployability due to service-connected headaches effective February 1, 2019.